Skip to content Skip to footer
Subscribe Now

NEWS

J&J Partners with Sail Biomedicines to Advance In Vivo CAR-T Therapies
Shots: J&J has entered strategic agreements & collaboration with Sail to advance its lead immune-mediated disease program & in vivo CAR-T platform, with the potential to expand the platform across additional therapeutic targets As per the deal, Sail will receive initial payments of $785M, incl. a $465M equity investment, with additional contingent payments of ~$140M…
July 30, 2026
AbCellera and Vertex Pharmaceuticals Team Up on T-Cell Engagers
Shots: AbCellera has entered into a collaboration with Vertex to research, develop, manufacture, & commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases & other conditions As per the deal, AbCellera will use its TCE platform for discovery & early development, while Vertex will fund all R&D costs and retain rights to develop & commercialize resulting…
July 29, 2026
Abbvie
AbbVie Secures EC Approval for Rinvoq to Treat Non-Segmental Vitiligo
Shots: The EC has approved Rinvoq (upadacitinib; 15mg, QD) for the treatment of pts (≥12yrs.) with non-segmental vitiligo (NSV) who are candidates for systemic therapy Approval was backed by the Viti-Up clinical program (M19-044; n=614), incl. 2 replicate trials assessing Rinvoq, where in Period A, pts were randomized to either Rinvoq or PBO for 48wks. &…
July 29, 2026
Elevation Spine Receives US FDA Clearance for Saber-C AVIA
Shots: The US FDA has granted 510(k) clearance to Saber-C AVIA, a zero-profile ACDF system featuring a porous 3D-printed titanium interbody with spike & screw fixation options Saber-C AVIA is designed to deliver the biomechanical stability of traditional plating in a lower-profile implant, featuring updated spike delivery tools, low-profile screw instruments, and a single-tray system…
July 29, 2026
CORE Biomedicine Licenses Preclinical Oncology Portfolio from Eisai
Shots: CORE Biomedicine has entered into a licensing agreement with Eisai, securing exclusive global rights to develop & commercialize multiple preclinical oncology programs As per the deal, CORE will obtain exclusive, global rights to certain preclinical oncology programs spanning distinct targets & biological pathways, providing CORE with a broad pipeline to develop next-generation precision medicines…
July 29, 2026
Hansoh Pharma Reports P-III (ARTEMIS-011) Trial Data on Ris-Rez for Osteosarcoma
Shots: Hansoh has reported P-III (ARTEMIS-011) trial data assessing risvutatug rezetecan (HS-20093), a B7-H3–directed ADC, vs CT in pts with osteosarcoma who had progressed or relapsed after receiving ≥2 prior lines of systemic therapy Trial met its 1EP of improved PFS as assessed by the IRC, with consistent benefits observed across 2EPs, incl. OS & investigator-assessed…
July 28, 2026
Load more